Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?

Bérengère Salomé; Amir Horowitz

doi:10.1158/2159-8290.CD-21-0613

Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?

Cancer Discov. 2021 Aug;11(8):1877-1878. doi: 10.1158/2159-8290.CD-21-0613.

Authors

Bérengère Salomé¹, Amir Horowitz²

Affiliations

¹ Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
² Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. amir.horowitz@mssm.edu.

PMID: 34344757
DOI: 10.1158/2159-8290.CD-21-0613

Abstract

Cancer is a strong risk factor for severe COVID-19 disease. In this issue of Cancer Discovery, Bilich and colleagues demonstrate impaired preexisting and newly generated CD4 T-cell response to SARS-CoV-2 in patients with cancer.See related article by Bilich et al., p. 1982.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

CD4-Positive T-Lymphocytes
COVID-19*
Humans
Immunity
Neoplasms* / drug therapy
Programmed Cell Death 1 Receptor
SARS-CoV-2

Substances

Programmed Cell Death 1 Receptor